title: Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT.
abstract: The purpose of this study was to assess the efficiency of fluorine-18 fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) in the characterisation and primary staging of suspicious renal masses, in comparison with computed tomography, the current standard imaging modality. Fifty-three FDG PET studies were performed within the framework of a prospective study: 35 for both characterisation and staging of a suspicious mass, and 18 for staging early after surgical removal of a renal cancer. In the characterisation of renal masses, a high rate of false negative results was observed, leading to a sensitivity, specificity and accuracy of 47%, 80% and 51% respectively, versus 97%, 0/5 and 83% respectively for CT. FDG PET detected all the sites of distant metastasis revealed by CT, as well as eight additional metastatic sites, leading to an accuracy of 94% versus 89% for CT. However, 36/53 patients (68%) did not have any distant metastasis on either CT or on PET. All but one of these patients had a low Fuhrman histological grade and a limited local stage (< or =pT2). We conclude that FDG PET does not offer any advantage over CT for the characterisation of renal masses but that it appears to be an efficient tool for the detection of distant metastasis in renal cancer. However, our data suggest that a selection process could be implemented to determine which patients should undergo PET. FDG PET could be performed in the event of a solitary metastasis or doubtful images on CT. Selection could also be based on adverse histological findings from nephrectomy specimens in order to perform staging early after nephrectomy.
authors.affiliation: Department of Nuclear Medicine, University Hospital, Caen, France. naide@club-internet.fr
authors.forename: Nicolas
authors.initials: N
authors.lastname: Aide
authors.forename: Olivier
authors.initials: O
authors.lastname: Cappele
authors.forename: Philippe
authors.initials: P
authors.lastname: Bottet
authors.forename: Henri
authors.initials: H
authors.lastname: Bensadoun
authors.forename: Armelle
authors.initials: A
authors.lastname: Regeasse
authors.forename: François
authors.initials: F
authors.lastname: Comoz
authors.forename: Franck
authors.initials: F
authors.lastname: Sobrio
authors.forename: Gérard
authors.initials: G
authors.lastname: Bouvard
authors.forename: Denis
authors.initials: D
authors.lastname: Agostini
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014055:Tomography, Emission-Computed / Q000379:methods*; D014057:Tomography, X-Ray Computed / Q000379:methods*; D014915:Whole-Body Counting / Q000379:methods
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18